For those following the health-care sector, there's no doubt that 2013 will be known as the year of the spinoff. However, the year started out with rampant speculation that another big acquisition was in the cards -- private equity firm Warburg Pincus was looking for a liquidity event for eye-care specialist Bausch & Lomb.

The potential price: $10 billion. The potential suitors: Abbott Labs (NYSE:ABT), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), Pfizer (NYSE:PFE), and Sanofi (NASDAQ:SNY). Follow along in the video below as Brenton Flynn runs through the likely final result.